QCG
BNTC icon

Quadrant Capital Group’s Benitec Biopharma BNTC Stock Holding History

Quadrant Capital Group’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.84K Hold
173
– – ﹤0.01% 2518
2025
Q4 		$2.33K Buy
+173
New +$2.39K ﹤0.01% 2497

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Quadrant Capital Group's BNTC Position: Q1 2026 in Review

Quadrant Capital Group held its Benitec Biopharma (BNTC) position steady in Q1 2026 at 173 shares worth $1.84K. The position accounts for ﹤0.01% of the portfolio, ranked #2518.

Quadrant Capital Group first reported a position in BNTC in Q4 2025 and has held it in 2 quarters since. The position peaked at $2.33K in Q4 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

  • Quadrant Capital Group held 173 shares of Benitec Biopharma worth $1.84K as of Q1 2026.
  • Quadrant Capital Group left its Benitec Biopharma share count unchanged in Q1 2026.
  • Benitec Biopharma made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2518 holding.
  • Quadrant Capital Group first reported a position in Benitec Biopharma in Q4 2025 and has held it in 2 quarters since.
  • Quadrant Capital Group's Benitec Biopharma position peaked at $2.33K in Q4 2025.
  • 88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.